what does of tirzepatide | GLP1 | Medical Weight Loss Tirzepatide, a New Era of
Description
Many patients do not see significant weight loss until they reach the 5-7mg dose range

While pooled data from the SURPASS clinical trial programme indicate that tirzepatide does not increase the risk of major cardiovascular events [61], definitive conclusions regarding its cardiovascular profile should await the results of SURPASS-CVOT, with its completion anticipated in late 2024 [60]

doi: 10.1016/j.molmet.2018.09.009 58 RetnakaranRZinmanB

Such food items supply insoluble fiber that affords bulk to the stool while maintaining healthy bowel function

The primary concern with any medication during lactation is whether it transfers into breast milk and, if so, whether it poses risks to the nursing infant
